This protein carries a mouse IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 109.8 kDa. The protein migrates as 125-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM Tris, 150 mM NaCl, Arginine, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human ACE2, Mouse IgG1 Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human ACE2, Mouse IgG1 Fc Tag(Cat. No. AC2-H5205) was more than 85% and the molecular weight of this protein is around 240-255 kDa verified by SEC-MALS.
Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Human ACE2, Mouse IgG1 Fc Tag (Cat. No. AC2-H5205) with a linear range of 0.4-6 ng/mL (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.